帕金森病（PD）是常见的神经系统变性疾病，典型的PD病理表现为脑中黑质多巴胺神经元退行性变和路易小体沉积，但这些改变不能完全解释PD产生的临床症状，目前PD的发病原因及机制尚不明确，尚未建立系统的早期诊断及保护治疗方式。随着诊断及治疗技术的提高，生物学标记物、脑网络及神经调控等有望为PD早期诊断、机制探索及个体化治疗提供基础。本文综述了PD在生物学标记物、脑网络研究及神经调控治疗领域的研究进展。
Parkinson's disease (PD) is a common neurodegenerative disorder. The clinical symptoms involve motor syndromes, such as bradykinesia, tremor, rigidity and gait disturbance, and non-motor syndromes, such as olfactory dysfunction, depression and constipation. The mechanism is still unknown. According to the classic pathology, it is the degeneration of dopaminergic neuron and Lewy body. However, this cannot explain all the manifestations. The studies of PD see a great progress in recent years. Our review focuses mainly on the biomarker, brain network and neuromodulation in PD.
[1] Kang J H, Mollenhauer B, Coffey C S, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease:The Parkin-son's Progression Markers Initiative study[J]. Acta Neuropathol, 2016, 131(6):935-949.
[2] Marques T M, Kuiperij H B, Bruinsma I B, et al. MicroRNAs in cere-brospinal fluid as potential biomarkers for Parkinson's disease and mul-tiple system atrophy[J]. Molecular Neurobiology, 2016:1-10.
[3] Shi M, Liu C, Cook T J, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease[J]. Acta neuropatho-logica, 2014, 128(5):639-650.
[4] Devic I, Hwang H J, Edgar J S, et al. Salivary α-synuclein and DJ-1:potential biomarkers for Parkinson's disease[J]. Brain, 2011, 134(7):e178-e178.
[5] Del Tredici K, Hawkes C H, Ghebremedhin E, et al. Lewy pathology in the submandibular gland of individuals with incidental Lewy body dis-ease and sporadic Parkinson's disease[J]. Acta neuropathologica, 2010,119(6):703-713.
[6] Cersósimo M G, Perandones C, Micheli F E, et al. Alpha-synuclein im-munoreactivity in minor salivary gland biopsies of Parkinson's disease patients[J]. Movement Disorders, 2011, 26(1):188-190.
[7] Wang N, Gibbons C H, Lafo J, et al. α-Synuclein in cutaneous auto-nomic nerves[J]. Neurology, 2013, 81(18):1604-1610.
[8] Donadio V, Incensi A, Leta V, et al. Skin nerve α-synuclein deposits a biomarker for idiopathic Parkinson disease[J]. Neurology, 2014, 82(15):1362-1369.
[9] Helmich R C, Hallett M, Deuschl G, et al. Cerebral causes and conse-quences of parkinsonian resting tremor:A tale of two circuits?[J]. Brain, 2012, 135(11):3206-3226.
[10] Mure H, Hirano S, Tang C C, et al. Parkinson's disease tremor-re-lated metabolic network:Characterization, progression, and treatment effects[J]. Neuroimage. 2011, 54(2):1244-53.
[11] Chen H M, Wang Z J, Fang J P, et al. Different Patterns of spontane-ous brain activity between tremor-dominant and postural Instability/gait difficulty subtypes of Parkinson's disease:A resting-state fMRI Study[J]. CNS Neuroscience & Therapeutics, 2015, 21(10):855-866.
[12] Alam M, Schwabe K, Krauss J K. The pedunculopontine nucleus area:critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation[J]. Brain, 2011, 134(1):11-23.
[13] Michely J, Volz L J, Barbe M T, et al. Dopaminergic modulation of mo-tor network dynamics in Parkinson's disease[J]. Brain, 2015:138(Pt 3):664-78.
[14] Málly J. Non-invasive brain stimulation (rTMS and tDCS) in patients with aphasia:Mode of action at the cellular level[J]. Brain research bulletin, 2013, 98:30-35.
[15] Kamble N, Netravathi M, Pal P K. Therapeutic applications of repeti-tive transcranial magnetic stimulation(rTMS) in movement disorders:A review[J]. Parkinsonism & Related Disorders, 2014, 20(7):695-707.
[16] Shukla A W, Shuster J J, Chung J W, et al. Repetitive transcranial magnetic stimulation(rTMS) therapy in Parkinson disease:A metaanalysis[J]. PM&R, 2016, 8(4):356-366.
[17] Arias P, Vivas J, Grieve K L, et al. Double-blind, randomized, place-bo controlled trial on the effect of 10 days low-frequency rTMS over the vertex on sleep in Parkinson's disease[J]. Sleep Medicine, 2010, 11(8):759-765.
[18] Nosko D, Ferraye M U, Fraix V, et al. Low-frequency versus high-fre-quency stimulation of the pedunculopontine nucleus area in Parkin-son's disease:a randomised controlled trial[J]. Journal of Neurology, Neurosurgery & Psychiatry, 2014:86(6):674-679.
[19] Velasco F, Llanos S, Avila-Rodriguez M A, et al. Metabolic changes induced by electrical stimulation of prelemniscal radiations for the treatment of parkinson disease[J]. Stereotactic and Functional Neuro-surgery, 2015, 93(5):333-341.
